TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01541436

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Remote Ischemic Preconditioning, Capsaicin, UV-B
Description: The participants will have one disposable tourniquet applied to the left mid thigh by research personnel. The participants will then be randomized to the treatment group or sham group. The treatment group will receive 3 cycles of RIPC to the left lower leg by occluding blood flow at the thigh with a pneumatic cuff. Each cycle will consist of 5 minutes of ischemia by inflating the cuff to 300 mmHg followed by 5 minutes of reperfusion. The sham group will have the cuff inflated to no more than 15mmHg for three cycles as described above. Areas of hypersensitivity and allodynia will be obtained every 40 min for 280 min following the end of capsaicin application.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Preconditioning, Capsaicin, UV-B
Description: The participants will have one disposable tourniquet applied to the left mid thigh by research personnel. The participants will then be randomized to the treatment group or sham group. The treatment group will receive 3 cycles of RIPC to the left lower leg by occluding blood flow at the thigh with a pneumatic cuff. Each cycle will consist of 5 minutes of ischemia by inflating the cuff to 300 mmHg followed by 5 minutes of reperfusion. The sham group will have the cuff inflated to no more than 15mmHg for three cycles as described above. Areas of hypersensitivity and allodynia will be obtained every 40 min for 280 min following the end of capsaicin application.
Study: NCT03189589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 500 µg
Description: GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 500 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 750 µg
Description: GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 750 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.
Study: NCT03836378

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BioXclude™
Description: The addition of BioXclude™ dehydrated human amnion-chorion membrane into deep pockets with scaling and root planing.
Study: NCT04223388

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 276
Description: 5 Billion CFU/dose, serving size = 1 capsule/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo product, serving size = 1 capsule/day
Study: NCT01947790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin group
Study: NCT02149121

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CT-P10
Description: 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CT-P10
Description: 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituxan
Description: US-licensed reference product, 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MabThera
Description: EU-approved reference product, 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
Study: NCT02702011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin high dose
Study: NCT04810442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nap
Description: 45-minute nap between scanning procedures
Study: NCT01568320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular Treatment (Zenith)
Description: Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
Study: NCT01859130

Intervention type: DEVICE
Group type: OTHER
Intervention: Zimmer Persona Total Knee System
Study: NCT00607152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasburicase
Description: 0.20mg/kg per day IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: 100mg tablets
Study: NCT03325972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The drug will be administered with a loading dose of 0.5 mcg/kg given over 20 min followed by an infusion at 0.6 mcg/kg/hr. The infusion will be stopped during closure of the fascia.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Saline
Description: Placebo will be administered with a loading dose of 0.5 mcg/kg given over 20 min followed by an infusion at 0.6 mcg/kg/hr. The infusion will be stopped during closure of the fascia.
Study: NCT02119117

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CoQ10
Description: This is a dietary supplement which will be administered daily to the patient for 3 months prior to IVF

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is a placebo which will be administered daily to the patient for 3 months prior to IVF.
Study: NCT03338985

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic analysis
Description: Genetic analysis of the samples taken during the surgery (hysterectomy or curettage resection) using CGH array technique.
Study: NCT04185350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA-MAL-Cys39-exendin-4
Description: After 68Ga-NOTA-MAL-Cys39-exendin-4 injection, the patient drank 300-500ml of water and urinated before the PET/CT scans.
Study: NCT04841993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis decoction
Description: A single 100 mL dose of cannabis decoction is administered containing 1.8 mg THC and 2.7 mg CBD.
Study: NCT02702011

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04841993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis oil
Description: A single administration of 15 drops (045 mL) of cannabis oil containing 1.8 mg THC and 3.8 mg CBD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized cannabis
Description: 100mg of vaporized cannabis is administered by Volcano vaporizer, wich containing 0.6-2 mg THC and 0.8-3 mg CBD
Study: NCT02705092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subliminal priming with subliminal reward stimuli
Description: Positive words as subliminal reward (displayed for 17 ms).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subliminal priming with supraliminal reward stimuli
Description: Positive words as supraliminal reward (displayed for 150 ms).
Study: NCT03695887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide Inhalant Product
Description: Nitrous Oxide Inhalant Product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive comparator
Study: NCT03321799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Description: A computer randomization system will be used on the day of surgery to allocate patients to either the conventional or NPWT dressing. Due to the nature of this study, blinding of patients and surgeons to their allocated cohort will not be possible.
Study: NCT01763866

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection
Study: NCT03321799

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sterile Antimicrobial Dressings
Description: Control group, current hospital standard.
Study: NCT01763866

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection
Study: NCT00145626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy and antibodies
Description: Study participants will receive a non-TBI based preparative regimen consisting of Cyclophosphamide, fludarabine, thiotepa, melphalan, and muromonab-CD3 (OKT3) followed by an infusion of a T-lymphocyte depleted haploidentical hematopoietic stem cell graft. Seven days posttransplant, participants will receive an infusion of additional donor derived cells called NK cells.
Study: NCT01763866

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection
Study: NCT00025363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study: NCT01763866

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Administered orally once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Administered orally once a day
Study: NCT04943159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide
Description: Group A is administered afamelanotide implant on Days 0, 21 and 42; Group B is administered afamelanotide implant on Days 0 and 28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide
Description: Group A is administered afamelanotide implant on Days 0, 21 and 42; Group B is administered afamelanotide implant on Days 0 and 28.
Study: NCT04226573

Intervention type: OTHER
Intervention: Preoperative anxiety levels
Description: Serums were separated from blood samples taken from all patients in the study, Using the anti-human TNF-α and IL-6 enzyme-linked immunosorbent assay (ELISA) kits in the Elisa device, the TNF-α and IL-6 cytokines will be measured to determine their concentration.~No routine blood will be drawn during the procedures. Preoperative anxiety levels will be evaluated with STAI-Continuity and STAI-Statefulness scale.
Study: NCT03936673

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrostomy
Study: NCT02133586

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ozone
Description: Exposure to 300ppb ozone with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or nitrogen dioxide) in a two-exposure series.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Exposure to 300ppb ozone with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or nitrogen dioxide) in a two-exposure series.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Exposure to 300ppb ozone with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or nitrogen dioxide) in a two-exposure series.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nitrogen dioxide
Description: Exposure to 500ppb nitrogen dioxide with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or ozone) in a two-exposure series.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nitrogen dioxide
Description: Exposure to 500ppb nitrogen dioxide with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or ozone) in a two-exposure series.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nitrogen dioxide
Description: Exposure to 500ppb nitrogen dioxide with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or ozone) in a two-exposure series.
Study: NCT02182791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EE/NET
Study: NCT03082170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FEES
Description: FEES test. During this test the investigators look at the pharynx and larynx of the participant while he eats and drinks Economy using number of textures aim to identify swallowing pathology.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SDQ
Description: The participant will fill a questionnaire containing 14 questions.These Questions rigorously test all aspects of the swallowing. High score in this test is consistent with swallowing disorder.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: data review
Description: Reviewing the data from the test summary of participants who have already undergone post operative swallowing assessment.
Study: NCT04126421

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prosthesis component (acetabular cup) E1 cup
Description: Semented acetabuar cup With E1 cup

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prosthesis component (acetabular cup) Marathon cup
Description: Semented acetabuar cup With Marathon cup
Study: NCT01467206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Long term follow up by a coordinating physiotherapist
Description: Monthly meetings with an coordinating physiotherapist who motivate and encourage the patient to do 60 minutes of weekly exercise and 30 minutes of daily physical activity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care as it is given to all stoke patients after stroke
Study: NCT02091323

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastric bypass surgery
Description: With the patient under intubation and general anesthesia, a pneumoperitoneum was created and the pressure was set to 15 mmHg. All LRYGB operations were performed using four trocars. Separate cardiac angle and hepatogastric ligament from the left gastric artery between 2 and 3 branch by hanging liver on the abdominal wall so as to enter into the lesser sac. Reveal the ligament of Treitz, lift the jejunum from the Treitz ligament 75 \~ 150 cm, connect the distal jejunum to the posterior wall of the stomach with a linear cutting staple by an end-to-side anastomosis and suture the common opening at last.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: gastric bypass surgery
Description: With the patient under intubation and general anesthesia, a pneumoperitoneum was created and the pressure was set to 15 mmHg. All LRYGB operations were performed using four trocars. Separate cardiac angle and hepatogastric ligament from the left gastric artery between 2 and 3 branch by hanging liver on the abdominal wall so as to enter into the lesser sac. Reveal the ligament of Treitz, lift the jejunum from the Treitz ligament 75 \~ 150 cm, connect the distal jejunum to the posterior wall of the stomach with a linear cutting staple by an end-to-side anastomosis and suture the common opening at last.
Study: NCT01509521

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: An infusion with a maximum of 3 mg/minute for maximum 60 minutes or if sideeffects develope.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: An infusion of maximum 4 mg/hour for maximum 60 minutes.
Study: NCT03022058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ear-EEG system
Description: Measurement of the neural activity in the brain by use of the Ear-EEG device, which is a customized earplug containing 6 embedded dry electrodes placed inside the ear canal and in the concha of the ear.
Study: NCT05985733

Intervention type: OTHER
Intervention: Biochemical analysis
Description: Oxidative stress and inflammation markers were analyzed in serum and saliva of TMD and healthy subjects.
Study: NCT00025363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study: NCT03054259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 1000mg rituximab infusions on days 1 and 15 (monoclonal antibody)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Description: 100mg infusion on days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 100mg infusion on days 1 and 15

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 250ml infusion on days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: 250ml infusion on days 1 and 15
Study: NCT04416620

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The PCOS pharmaceutical care service
Description: The intervention was provided in the format of oral plus written information. The information provided included the importance of exercise and motivational messages to exercise more at home or in the gym.~The 2nd part was about the importance of decreasing the stress levels. Participants were informed to perform a simple breathing exercise on daily basis twice a day.~The 3rd part aimed at improving participants' diets. They were informed to follow specific diet recommendations and to avoid certain types of food, explaining to them how it may negatively affect their PCOS condition.~The 4th part was about the PCOS treatment that was discussed with the participants. Females were advised on the importance of using their correct treatment. They were informed of the importance of adhering to their prescribed medications, accepting that it was a long-term treatment plan, and to consult with their specialist if their treatment was not effective, or in the case of medication side effects.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The PCOS pharmaceutical care service
Description: The intervention was provided in the format of oral plus written information. The information provided included the importance of exercise and motivational messages to exercise more at home or in the gym.~The 2nd part was about the importance of decreasing the stress levels. Participants were informed to perform a simple breathing exercise on daily basis twice a day.~The 3rd part aimed at improving participants' diets. They were informed to follow specific diet recommendations and to avoid certain types of food, explaining to them how it may negatively affect their PCOS condition.~The 4th part was about the PCOS treatment that was discussed with the participants. Females were advised on the importance of using their correct treatment. They were informed of the importance of adhering to their prescribed medications, accepting that it was a long-term treatment plan, and to consult with their specialist if their treatment was not effective, or in the case of medication side effects.
Study: NCT01714349

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve Transfer
Description: A nerve transfer procedure will be individualized to each patient's functional deficit.
Study: NCT00145626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miltenyi Biotec CliniMACS
Description: Stem cell selection device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation
Description: Allogeneic natural killer (NK)cell infusion
Study: NCT03367884

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neck dissection followed by radiotherapy(50Gy) according to risk factors
Description: Neck dissection followed by radiotherapy(50Gy) according to risk factors

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Definitive radiotherapy
Description: Definitive radiotherapy (70Gy)
Study: NCT03374020

Intervention type: DEVICE
Intervention: Notal OCT
Description: Imaging using Notal OCT

Intervention type: DEVICE
Intervention: Notal OCT
Description: Imaging using Notal OCT

Intervention type: DEVICE
Intervention: Notal OCT
Description: Imaging using Notal OCT

Intervention type: DEVICE
Intervention: Notal OCT
Description: Imaging using Notal OCT
Study: NCT04542122

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Choices and judgements
Description: In the intervention arm, the participant is asked to answer clinical cases in a reverse order from the control group (control has to make moral choices then judge somebody else's choices ; intervention has to judge moral choices first, then make his own)
Study: NCT05106348

Intervention type: DIAGNOSTIC_TEST
Intervention: Aerobic Fitness Test
Description: aerobic fitness test to assess wheelchair rugby players capacity
Study: NCT01740687

Intervention type: DEVICE
Intervention: ESS305 (Essure, BAY1454032)
Description: Essure Permanent Birth Control

Intervention type: PROCEDURE
Intervention: NovaSure
Description: Nova Sure Endometrial Ablation
Study: NCT06058962

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Suramin Sodium
Description: Suramin sodium is a sodium salt form of suramin, an antitrypanosomal compound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suramin Sodium
Description: Suramin sodium is a sodium salt form of suramin, an antitrypanosomal compound.
Study: NCT01763866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Administered orally once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Administered orally once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection
Study: NCT06058962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suramin Sodium
Description: Suramin sodium is a sodium salt form of suramin, an antitrypanosomal compound.
Study: NCT02805452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Succinate of Solifenacin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Succinate of Solifenacin